Papillary renal cell carcinoma

Last updated
Papillary renal cell carcinoma
Histopathology of papillary renal cell carcinoma type 1.jpg
Papillary renal cell carcinoma, type 1, characterised by tubulopapillary architecture with admixed foamy histiocytes in the papillary cores.
Specialty Oncology
Symptoms Hematuria, flank pain, palpable abdominal mass
Diagnostic method Medical Image Test (ultrasound, computed tomography, magnetic resonance imaging)
TreatmentNephrectomy, partial nephretocmy, targeted molecular therapy
Prognosis 82-90% for five-year survival rate

Papillary renal cell carcinoma (PRCC) is a malignant, heterogeneous tumor originating from renal tubular epithelial cells of the kidney, which comprises approximately 10-15% of all kidney neoplasms. [1] Based on its morphological features, PRCC can be classified into two main subtypes, which are type 1 (basophilic) and type 2 (eosinophilic). [2]

Contents

As with other types of renal cell cancer, most cases of PRCC are discovered incidentally without showing specific signs or symptoms of cancer. [3] In advanced stages, hematuria, flank pain, and abdominal mass are the three classic manifestation. [4] While a complete list of the causes of PRCC remains unclear, several risk factors were identified to affect PRCC development, such as genetic mutations, kidney-related disease, environmental and lifestyle risk factors. [5] For pathogenesis, type 1 PRCC is mainly caused by MET gene mutation while type 2 PRCC is associated with several different genetic pathways. [6] For diagnosis, PRCC is detectable through computed tomography (CT) scans or magnetic resonance imaging (MRI), which commonly present a small homogeneous hyposvascular tumor. [7] Nephrectomy or partial nephrectomy is usually recommended for PRCC treatment, often accompanied with several targeted molecular therapies to inhibit metastatic spread. [8] [9] PRCC patients are predominantly male with a mean age of 52–66 years. [10] When compared to conventional clear cell renal cell carcinoma (RCC), the prognosis of non-metastatic PRCC is more favorable, whereas a relatively worse outcome was reported in patients with metastatic disease. [11] Globally, the incidence of PRCC ranges between 3,500 to 5,000 cases, while it greatly varies depending on gender, age, and race/ethnicity. [12]

Classification

In 2014, PRCC was first acknowledged as a renal tumor subtype by the World Health Organization (WHO) considering its distinct genetic, molecular and histologic characteristics. [10] It is further divided into type 1 and type 2 based on morphological features. [13]

Type 1 Papillary Renal Cell Carcinoma

Type 1 PRCC, also known as a renal tumor caused by a genetic predisposition of hereditary papillary renal cancer syndrome, compromises approximately 25% of all PRCCs. [14] [15] In the perspective of immunochemistry, it has a profile of strong CK7 and alpha-methyl acyl-CoA racemase (AMACR) expression at most focal CA-IX expression. [16] Histologically, its epithelium is composed of relatively small-sized simple cuboidal cells lined in a single layer. [17] These cells are well-characterized by basophilic cytoplasm. [18] Due to its solid growth, an extremely compact papillary architecture is often observed. [16] Other morphological characteristics include intracellular hemosiderin and foamy macrophages placed inside of papillary fibrovascular cores or psammoma bodies. [19] In general, the nuclei of type 1 PRCC belong to grade 1-2 of the Fuhrman system. [16]

Type 2 Papillary renal cell carcinoma

A micrograph of Type 2 PRCC, showing cells containing abundant eosinophilic granular cytoplasm with prominent nucleoli. Type 2 Papillary Renal Cell Carcinoma.jpg
A micrograph of Type 2 PRCC, showing cells containing abundant eosinophilic granular cytoplasm with prominent nucleoli.

Accounting for 25% of PRCCs, type 2 PRCC is the pathological subtype that is most commonly associated with hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. [14] [15] When compared to type 1, it shows more variation in protein expression mostly by loss of CK7. [16] In a gross examination, it shows papillae covered by large cells abundant in eosinophilic cytoplasm. [18] Its large spherical nuclei on papillary cores are arranged in a pseudo-stratified manner. [16] Unlike type 1 PRCC, foamy macrophages and psammoma bodies are less common in case of type 2. [15] The majority of type 2 PRCC has high Fuhrman grade nuclei with prominent nucleoli. [16]

Signs and Symptoms

Due to its asymptomatic nature, PRCC is often undetectable, and the majority of cases are incidentally diagnosed during the radiological workup of unrelated diseases. [3] [8] Its clinical manifestations are similar to those of clear cell RCC, which are the classical triad of renal cell carcinoma (hematuria, flank pain and palpable abdominal mass; only 6-10% of patients) or even nonspecific symptoms including fatigue, weight loss, fever, and anorexia. [4] [10] [21] Since early diagnosis is relatively uncommon, PRCC patients may experience symptoms caused by the metastatic spread to secondary sites. Specifically, metastasis occurs most frequently in the lungs followed by bone and the brain, exhibiting a wide range of symptoms including bone pain to a persistent cough. [8] [21]

Causes

Currently, the exact cause of PRCC remains unclear. Possible risk factors have been identified that contribute to PRCC development, which include genetic mutations, hereditary syndrome, renal injuries, and lifestyle factors. Germline mutation of c-MET oncogene and fumarate hydratase gene elevates the risk of type 1 and type 2 PRCC respectively through distinct signaling pathways. [22] [23] Regarding hereditary conditions, patients with hereditary papillary renal cancer syndrome showed a greater risk of type 1 PRCC, whereas those with hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome have an increased risk of type 2 PRCC. [24] [5] Moreover, patients who experienced chronic kidney diseases or acute kidney injury exhibited a higher incidence of PRCC. [25] [26] Additionally, other risk factors such as smoking, obesity, and high blood pressure can influence the pathogenesis of PRCC. [5]

Pathogenesis

An overview of the MET molecular pathway in PRCC MET-pathway.jpg
An overview of the MET molecular pathway in PRCC

Different molecular mechanisms are involved in PRCC development, which further result in distinct histologic features and clinical outcomes.[ citation needed ]

Type 1 PRCC is caused by a genetic mutation or a gain in chromosome 7 where the MET gene is positioned, resulting in the promotion of oncogenic pathways in renal epithelial cells. [6] Typically, the MET gene is upregulated for renal tissue repair and regeneration by encoding the receptor tyrosine kinase c-MET of hepatocyte growth factor. [6] However, activation of the oncogenic pathway in the MET gene will manifest invasion, anti-apoptosis, angiogenesis, and metastasis. [6]

Type 2 PRCC is associated with irregularity of several signaling pathways, which includes CDKN2A silencing, mutation in chromatin-modifying genes, and a GpG island methylator phenotype (CIMP). [27] CDKN2A is a tumor suppressor gene, while loss of its expression results in enhanced tumorigenesis and metastasis. [27] [28] Moreover, mutation of gene involved in chromatin remodeling (SETD2, BAP1, or PBRM) may lead to higher rate of TFE3/TFEB fusion. [27] Additionally, CIMP papillary renal cell carcinoma tumors exhibited somatic FH gene mutation, which is closely associated with HLRCC syndrome. [23]

Diagnosis

Currently, cross-sectional imaging with computed tomography (CT) and magnetic resonance imaging (MRI) is known as the best option for diagnosing papillary renal tumors. [29]

Unenhanced (left) and nephrographic phase (right) CT scans display a 1-cm low-attenuation PRCC tumor (arrow) in the right renal cortex CT scan of PRCC in a 54-year-old woman.png
Unenhanced (left) and nephrographic phase (right) CT scans display a 1-cm low-attenuation PRCC tumor (arrow) in the right renal cortex

Computed tomography (CT)

Contrast-enhanced computed tomography (CT) is most commonly used to identify the subtypes of RCC. PRCC can be differentiated from other types of RCC due to its distinguishing features, displaying a small hypovascular renal tumor on T2 weighted images. [7] Typically, PRCC tends to appear homogeneous while clear cell RCC is likely to be in a heterogeneous form when the tumor is less than 3 cm in diameter. [30] Comparatively, in cases of tumors larger than 3 cm in diameter, PRCC is generally heterogeneous with areas of necrosis and hemorrhage compared to chromophobe RCC. [8] [31] Solid, small PRCC tumors (<3 cm in diameter) are more easily viewed on nephrographic, excretory phase images rather than on unenhanced, corticomedullary phase images. [8]

Magnetic resonance imaging (MRI)

Magnetic resonance imaging (MRI) is recommended instead of CT for patients with an allergy to iodinated contrast materials. [8] As some renal tumors do not enhance significantly on CT, MRI examination is required to be performed with more sensitive contrast enhancement. [7] On MRI, the distinct features of PRCC are fibrous capsules and homogeneously low single intensity on both T1- and T2-weighted images. [8] [32] Specifically, PRCC exhibits hypointensity due to its dense collagenous matrix or deposition of calcium and hemosiderin within the tumor. [33] Such visual features help PRCC to be differentiated from clear cell RCC, which has heterogeneously higher single intensity shown on T2-weighted images. [8] [32] PRCC displays the smallest tumor-to-cortex enhancement at corticomedullary and nephrographic phases when juxtaposed with clear cell and chromophobe RCCs. [32]

Grading System

Papillary renal cell carcinoma type 1, grade 2: Nucleoli (one annotated by arrows) are conspicuous and eosinophilic at x {\displaystyle \times } 400 magnification and visible but not prominent at x {\displaystyle \times } 100 magnification. Histopathology of papillary renal cell carcinoma type 1 grade 2, very high magnification, annotated.jpg
Papillary renal cell carcinoma type 1, grade 2: Nucleoli (one annotated by arrows) are conspicuous and eosinophilic at 400 magnification and visible but not prominent at 100 magnification.

The WHO/ISUP system is histological tumor grading system for renal cell carcinoma, suggested by the International Society of Urologic Pathologists (ISUP) in 2012 to diagnose tumor grades based on nucleolar prominence. [34] Currently recommended by the WHO, this four-tiered WHO/ISUP grading system has also been validated for PRCC. [34]

WHO/ISUP system for Papillary Renal Cell Carcinoma (PRCC) Grading [35]
GradeDefinition
1Nucleoli are absent or inconspicuous and basophilic at 400 magnification.
2Nucloeli are conspicuous and eosinophilic at 400 magnification and visible but not prominent at 100 magnification.
3Nucleoli are conspicuous and eosinophilic at 100 magnification
4There is extreme nuclear pleomorphism, multinucleate giants cells, and/or rhabdoid an/or sarcomatoid differentiation

Earlier, the Fuhrman system was largely used, and was similarly based on nuclear features. [36]

Treatment

First-line treatment for metastatic PRCC has not been standardized. Thus, similar treatment approaches for clear cell RCC have been used for PRCC, even though it has a distinct tumor histology. [9] [37]

Surgery

Nephrectomy or nephron-sharing partial nephrectomy is widely recommended to reduce the risk of metastasis by eliminating all or part of the kidney. [8] Surgery procedures for PRCC depend on the patient's status and are very similar to procedures performed on RCC patients.[ citation needed ]

Targeted Therapy

Several medications that target molecular pathways in RCC have been possible options for advanced and metastatic PRCC. [9] Among different medications, tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors are effective in inhibiting angiogenesis, blocking growth and suppressing spread of the tumor. [38] Sunitinib, sorafenib, and axitinib are TKIs with anti-vascular endothelial growth factor (VEGF), which inhibit cellular signaling by targeting multiple receptor tyrosine kinase. [38] [39] [40] [41] Everolimus and temsirolimus are used in deregulating the mTOR pathway. [42] [43] Specifically, mTOR inhibitors have crucial roles in regulating cell growth, cell proliferation and metabolism of highly active tumor cells. [38] Other targeted agents such as MET inhibitors, epidermal growth factor receptor (EGFR) inhibitors, and monoclonal antibodies, are also promising treatment approaches for PRCC. [9] Foretinib is one example of a multikinase inhibitor targeting c-MET. [44] Considering that MET gene mutation is one oncogenic pathway of PRCC, MET inhibitors like tivantinib and volitinib are currently being investigated as a new targeted therapy option. [9] [44]

Prognosis

The five-year survival rate of PRCC has been reported as 82-90%, which is slightly higher than that of other kidney cancers. [45] The reduced survival rate has been positively correlated to several factors, which are high nuclear grade and stage, vascular invasion, DNA aneuploidy, and more. [46] Patients with type 1 PRCC have significantly improved survival rates than those with type 2, which is a reflection of its lower TNM stage with a well-encapsulated tumor. [47] Compared to other common types of RCC, PRCC exhibits a relatively lower risk of tumor recurrence and cancer-related death after nephrectomy. [48] Specifically, the cancer-specific survival rate at five years following surgery with PRCC has reached up to 91%, while clear cell RCC and chromophobe RCC were 72% and 88%, respectively. [46]

Epidemiology

Among different histologic subtypes of RCC, PRCC is the second most predominant type and accounts for 10-15% of all renal tumors. [49] In the case of the United States, it is estimated that the incidence of PRCC will rise to 3,500 to 5,000 cases annually. [12] Generally, PRCC is more prevalent among men than women, while the reported sex ratio (M: F) varies from 1.8:1 to 3.8:1. [50] The mean age at presentation is identified as 52–66 years old; however, no statistically significant difference was found in the incidence of PRCC between the younger (< 40 years) and older adult groups (>40 years). [10] [51] In terms of racial variation, several studies have proven that people with African or Afro-Caribbean ancestry tend to have higher chances of being diagnosed with PRCC. According to the National Cancer Database, PRCC was more common in the Non-Hispanic Black population (38.9%) when compared to other races – Asian American (18.0%), Non-Hispanic White (13.2%), and Hispanic White populations (6.1%). [52]

Related Research Articles

<span class="mw-page-title-main">Thyroid neoplasm</span> Medical condition

Thyroid neoplasm is a neoplasm or tumor of the thyroid. It can be a benign tumor such as thyroid adenoma, or it can be a malignant neoplasm, such as papillary, follicular, medullary or anaplastic thyroid cancer. Most patients are 25 to 65 years of age when first diagnosed; women are more affected than men. The estimated number of new cases of thyroid cancer in the United States in 2010 is 44,670 compared to only 1,690 deaths. Of all thyroid nodules discovered, only about 5 percent are cancerous, and under 3 percent of those result in fatalities.

<span class="mw-page-title-main">Endometrial cancer</span> Uterine cancer that is located in tissues lining the uterus

Endometrial cancer is a cancer that arises from the endometrium. It is the result of the abnormal growth of cells that have the ability to invade or spread to other parts of the body. The first sign is most often vaginal bleeding not associated with a menstrual period. Other symptoms include pain with urination, pain during sexual intercourse, or pelvic pain. Endometrial cancer occurs most commonly after menopause.

<span class="mw-page-title-main">Renal cell carcinoma</span> Medical condition

Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases. RCC occurrence shows a male predominance over women with a ratio of 1.5:1. RCC most commonly occurs between 6th and 7th decade of life.

<span class="mw-page-title-main">Kidney cancer</span> Medical condition

Kidney cancer, also known as renal cancer, is a group of cancers that starts in the kidney. Symptoms may include blood in the urine, lump in the abdomen, or back pain. Fever, weight loss, and tiredness may also occur. Complications can include spread to the lungs or brain.

<span class="mw-page-title-main">Collecting duct system</span> Kidney system

The collecting duct system of the kidney consists of a series of tubules and ducts that physically connect nephrons to a minor calyx or directly to the renal pelvis. The collecting duct system is the last part of nephron and participates in electrolyte and fluid balance through reabsorption and excretion, processes regulated by the hormones aldosterone and vasopressin.

<span class="mw-page-title-main">Birt–Hogg–Dubé syndrome</span> Rare autosomal dominant cancer syndrome

Birt–Hogg–Dubé syndrome (BHD), also Hornstein–Birt–Hogg–Dubé syndrome, Hornstein–Knickenberg syndrome, and fibrofolliculomas with trichodiscomas and acrochordons is a human, adult onset, autosomal dominant genetic disorder caused by the FLCN gene. It can cause susceptibility to kidney cancer, renal and pulmonary cysts, and noncancerous tumors of the hair follicles, called fibrofolliculomas. The symptoms seen in each family are unique, and can include any combination of the three symptoms. Fibrofolliculomas are the most common manifestation, found on the face and upper trunk in over 80% of people with BHD over the age of 40. Pulmonary cysts are equally common (84%), but only 24% of people with BHD eventually experience a collapsed lung. Kidney tumors, both cancerous and benign, occur in 14–34% of people with BHD; the associated kidney cancers are often rare hybrid tumors.

<span class="mw-page-title-main">Invasive carcinoma of no special type</span> Medical condition

Invasive carcinoma of no special type (NST) is also referred to as invasive ductal carcinoma or infiltrating ductal carcinoma(IDC) and invasive ductal carcinoma, not otherwise specified (NOS). Each of these terms represents to the same disease entity, but for international audiences this article will use invasive carcinoma NST because it is the preferred term of the World Health Organization (WHO).

<span class="mw-page-title-main">Sunitinib</span> Cancer medication

Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.

<span class="mw-page-title-main">Papillary thyroid cancer</span> Medical condition

Papillary thyroid cancer is the most common type of thyroid cancer, representing 75 percent to 85 percent of all thyroid cancer cases. It occurs more frequently in women and presents in the 20–55 year age group. It is also the predominant cancer type in children with thyroid cancer, and in patients with thyroid cancer who have had previous radiation to the head and neck. It is often well-differentiated, slow-growing, and localized, although it can metastasize.

<span class="mw-page-title-main">Transitional cell carcinoma</span> Medical condition

Transitional cell carcinoma, also called urothelial carcinoma, is a type of cancer that typically occurs in the urinary system. It is the most common type of bladder cancer and cancer of the ureter, urethra, and urachus. Symptoms of urothelial carcinoma in the bladder include hematuria. Diagnosis includes urine analysis and imaging of the urinary tract (cystoscopy). Transitional cell carcinomas arise from the transitional epithelium, a tissue lining the inner surface of these hollow organs. When the term "urothelial" is used, it specifically refers to a carcinoma of the urothelium, meaning a transitional cell carcinomas of the urinary system.

<span class="mw-page-title-main">Mesoblastic nephroma</span> Medical condition

Congenital mesoblastic nephroma, while rare, is the most common kidney neoplasm diagnosed in the first three months of life and accounts for 3-5% of all childhood renal neoplasms. This neoplasm is generally non-aggressive and amenable to surgical removal. However, a readily identifiable subset of these kidney tumors has a more malignant potential and is capable of causing life-threatening metastases. Congenital mesoblastic nephroma was first named as such in 1967 but was recognized decades before this as fetal renal hamartoma or leiomyomatous renal hamartoma.

<span class="mw-page-title-main">Collecting duct carcinoma</span> Type of kidney cancer

Collecting duct carcinoma (CDC) is a type of kidney cancer that originates in the papillary duct of the kidney. It is rare, accounting for 1-3% of all kidney cancers. It is also recently described; a 2002 review found just 40 case reports worldwide. Previously, due to its location, CDC was commonly diagnosed as renal cell carcinoma or a subtype of renal cell carcinoma. However, CDC does not respond well to chemotherapy drugs used for renal cell carcinoma, and progresses and spreads more quickly.

<span class="mw-page-title-main">Renal medullary carcinoma</span> Cancer affecting the kidneys

Renal medullary carcinoma is a rare type of cancer that affects the kidney. It tends to be aggressive, difficult to treat, and is often metastatic at the time of diagnosis. Most individuals with this type of cancer have sickle cell trait or rarely sickle cell disease, suggesting that the sickle cell trait may be a risk factor for this type of cancer.

<span class="mw-page-title-main">Kidney tumour</span> Medical condition

Kidney tumours are tumours, or growths, on or in the kidney. These growths can be benign or malignant.

Targeted therapy of lung cancer refers to using agents specifically designed to selectively target molecular pathways responsible for, or that substantially drive, the malignant phenotype of lung cancer cells, and as a consequence of this (relative) selectivity, cause fewer toxic effects on normal cells.

<span class="mw-page-title-main">Adenocarcinoma of the lung</span> Medical condition

Adenocarcinoma of the lung is the most common type of lung cancer, and like other forms of lung cancer, it is characterized by distinct cellular and molecular features. It is classified as one of several non-small cell lung cancers (NSCLC), to distinguish it from small cell lung cancer which has a different behavior and prognosis. Lung adenocarcinoma is further classified into several subtypes and variants. The signs and symptoms of this specific type of lung cancer are similar to other forms of lung cancer, and patients most commonly complain of persistent cough and shortness of breath.

<span class="mw-page-title-main">Mucinous tubular and spindle cell carcinoma</span> Medical condition

Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare subtype of renal cell carcinoma (RCC), that is included in the 2004 WHO classification of RCC. MTSCC is a rare neoplasm and is considered as a low-grade entity. It may be a variant of papillary RCC. This tumor occurs throughout life and is more frequent in females.

<span class="mw-page-title-main">Hereditary leiomyomatosis and renal cell cancer syndrome</span> Medical condition

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) or Reed's syndrome is rare autosomal dominant disorder associated with benign smooth muscle tumors and an increased risk of renal cell carcinoma. It is characterised by multiple cutaneous leiomyomas and, in women, uterine leiomyomas. It predisposes for renal cell cancer, an association denominated hereditary leiomyomatosis and renal cell cancer, and it is also associated with increased risk of uterine leiomyosarcoma. The syndrome is caused by a mutation in the fumarate hydratase gene, which leads to an accumulation of fumarate. The inheritance pattern is autosomal dominant and screening can typically begin in childhood.

<span class="mw-page-title-main">Squamous-cell carcinoma of the lung</span> Medical condition

Squamous-cell carcinoma (SCC) of the lung is a histologic type of non-small-cell lung carcinoma (NSCLC). It is the second most prevalent type of lung cancer after lung adenocarcinoma and it originates in the bronchi. Its tumor cells are characterized by a squamous appearance, similar to the one observed in epidermal cells. Squamous-cell carcinoma of the lung is strongly associated with tobacco smoking, more than any other forms of NSCLC.

<span class="mw-page-title-main">Toni Choueiri</span> American medical oncologist

Toni K. Choueiri is a Lebanese American medical oncologist and researcher. He is the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School and Director of the Lank Center for Genitourinary Oncology at the Dana–Farber Cancer Institute. His work has led to the establishment of several novel drugs and prognostic factors in advanced renal cell carcinoma (RCC). Choueiri also co-established the International metastatic database Consortium with Daniel Heng. His biomarker work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy.

References

  1. ↑ Cairns P (2011). "Renal cell carcinoma". Cancer Biomarkers. 9 (1–6): 461–73. doi:10.3233/CBM-2011-0176. PMC   3308682 . PMID   22112490.
  2. ↑ Lee J, Chae HK, Lee W, Nam W, Lim B, Choi SY, et al. (2018-12-28). "Comparison of Prognosis in Types 1 and 2 Papillary Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma in T1 Stage". The Korean Journal of Urological Oncology. 16 (3): 119–125. doi: 10.22465/kjuo.2018.16.3.119 .
  3. 1 2 Encyclopedia of Cancer. Academic Press. 2018-10-12. ISBN   978-0-12-812485-7.
  4. 1 2 Courthod G, Tucci M, Di Maio M, Scagliotti GV (October 2015). "Papillary renal cell carcinoma: A review of the current therapeutic landscape". Critical Reviews in Oncology/Hematology. 96 (1): 100–12. doi:10.1016/j.critrevonc.2015.05.008. hdl: 2318/1564896 . PMID   26052049.
  5. 1 2 3 "Risk Factors for Kidney Cancer". www.cancer.org. Retrieved 2020-04-08.
  6. 1 2 3 4 5 Rhoades Smith KE, Bilen MA (November 2019). "A Review of Papillary Renal Cell Carcinoma and MET Inhibitors". Kidney Cancer. 3 (3): 151–161. doi:10.3233/KCA-190058. PMC   6918905 . PMID   31867475.
  7. 1 2 3 Couvidat C, Eiss D, Verkarre V, Merran S, Corréas JM, Méjean A, Hélénon O (November 2014). "Renal papillary carcinoma: CT and MRI features". Diagnostic and Interventional Imaging. 95 (11): 1055–63. doi: 10.1016/j.diii.2014.03.013 . PMID   25443332.
  8. 1 2 3 4 5 6 7 8 9 10 Vikram R, Ng CS, Tamboli P, Tannir NM, Jonasch E, Matin SF, et al. (2009-05-01). "Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease". Radiographics. 29 (3): 741–54, discussion 755–7. doi:10.1148/rg.293085190. PMID   19448113.
  9. 1 2 3 4 5 Bourlon MT, Meneses-Medina M, Vázquez-Manjarrez S, Bustamante-Romero FM, Gallegos-Garza AC, Lam ET (November 2015). "A Patient With Newly Diagnosed Metastatic Type 2 Papillary Renal Cell Carcinoma". Oncology (Williston Park, N.Y.). 29 (11): 880–6. PMID   26573066.
  10. 1 2 3 4 International Agency for Research on Cancer (2004). Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC. ISBN   978-92-832-2415-0.
  11. ↑ Klatte T, Gallagher KM, Afferi L, Volpe A, Kroeger N, Ribback S, et al. (October 2019). "The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort". BMC Medicine. 17 (1): 182. doi: 10.1186/s12916-019-1419-1 . PMC   6775651 . PMID   31578141.
  12. 1 2 Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. (2005). "Cancer statistics, 2005". CA: A Cancer Journal for Clinicians. 55 (1): 10–30. doi: 10.3322/canjclin.55.1.10 . PMID   15661684. S2CID   22356919.
  13. ↑ Weidner N, Cote RJ, Suster S, Weiss LM (2009-07-08). Modern Surgical Pathology E-Book. Elsevier Health Sciences. ISBN   978-1-4377-1958-1.
  14. 1 2 Haas NB, Nathanson KL (January 2014). "Hereditary kidney cancer syndromes". Advances in Chronic Kidney Disease. 21 (1): 81–90. doi:10.1053/j.ackd.2013.10.001. PMC   3872053 . PMID   24359990.
  15. 1 2 3 "Papillary renal cell carcinoma (PRCC)". www.pathologyoutlines.com. Retrieved 2020-04-08.
  16. 1 2 3 4 5 6 Warren AY, Harrison D (December 2018). "WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies". World Journal of Urology. 36 (12): 1913–1926. doi:10.1007/s00345-018-2447-8. PMC   6280811 . PMID   30123932.
  17. ↑ Chevarie-Davis M, Riazalhosseini Y, Arseneault M, Aprikian A, Kassouf W, Tanguay S, et al. (July 2014). "The morphologic and immunohistochemical spectrum of papillary renal cell carcinoma: study including 132 cases with pure type 1 and type 2 morphology as well as tumors with overlapping features". The American Journal of Surgical Pathology. 38 (7): 887–94. doi:10.1097/PAS.0000000000000247. PMID   24919183. S2CID   1998988.
  18. 1 2 Bukowski RM, Novick A (2009-12-03). Clinical Management of Renal Tumors. Springer Science & Business Media. ISBN   978-1-60327-149-3.
  19. ↑ "Right Kidney". College of American Pathologists. Retrieved 2020-04-19.
  20. 1 2 Muglia VF, Prando A (2014-04-10). "Renal cell carcinoma: histological classification and correlation with imaging findings". Radiologia Brasileira. 48 (3): 166–74. doi: 10.1590/0100-3984.2013.1927 . PMC   4492569 . PMID   26185343.
  21. 1 2 "papillary renal cell carcinoma". www.ebi.ac.uk. Retrieved 2020-04-08.
  22. ↑ "What Causes Kidney Cancer?". www.cancer.org. Retrieved 2020-04-08.
  23. 1 2 Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, et al. (January 2016). "Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma". The New England Journal of Medicine. 374 (2): 135–45. doi:10.1056/NEJMoa1505917. PMC   4775252 . PMID   26536169.
  24. ↑ "Hereditary Papillary Renal Carcinoma". Cancer.Net. 2012-06-25. Retrieved 2020-04-08.
  25. ↑ van de Pol JA, van den Brandt PA, Schouten LJ (February 2019). "Kidney stones and the risk of renal cell carcinoma and upper tract urothelial carcinoma: the Netherlands Cohort Study". British Journal of Cancer. 120 (3): 368–374. doi:10.1038/s41416-018-0356-7. PMC   6353869 . PMID   30563989.
  26. ↑ Peired AJ, Antonelli G, Angelotti ML, Allinovi M, Guzzi F, Sisti A, et al. (March 2020). "Acute kidney injury promotes development of papillary renal cell adenoma and carcinoma from renal progenitor cells". Science Translational Medicine. 12 (536): eaaw6003. doi:10.1126/scitranslmed.aaw6003. PMID   32213630. S2CID   214671587.
  27. 1 2 3 Malouf GG, Joseph RW, Shah AY, Tannir NM (May 2017). "Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities". Clinical Advances in Hematology & Oncology. 15 (5): 409–418. PMID   28591094.
  28. ↑ Zhao R, Choi BY, Lee MH, Bode AM, Dong Z (June 2016). "Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer". eBioMedicine. 8: 30–39. doi: 10.1016/j.ebiom.2016.04.017 . PMC   4919535 . PMID   27428416.
  29. ↑ "Genetics of Kidney Cancer (Renal Cell Cancer) (PDQ®)–Health Professional Version". National Cancer Institute. 2013-11-01. Retrieved 2020-04-08.
  30. ↑ Herts BR, Coll DM, Novick AC, Obuchowski N, Linnell G, Wirth SL, Baker ME (February 2002). "Enhancement characteristics of papillary renal neoplasms revealed on triphasic helical CT of the kidneys". AJR. American Journal of Roentgenology. 178 (2): 367–72. doi:10.2214/ajr.178.2.1780367. PMID   11804895.
  31. ↑ Kim JK, Kim TK, Ahn HJ, Kim CS, Kim KR, Cho KS (June 2002). "Differentiation of subtypes of renal cell carcinoma on helical CT scans". AJR. American Journal of Roentgenology. 178 (6): 1499–506. doi:10.2214/ajr.178.6.1781499. PMID   12034628.
  32. 1 2 3 Gurel S, Narra V, Elsayes KM, Siegel CL, Chen ZE, Brown JJ (2013-03-11). "Subtypes of renal cell carcinoma: MRI and pathological features". Diagnostic and Interventional Radiology. 19 (4): 304–11. doi:10.5152/dir.2013.147. PMID   23439256.
  33. ↑ Hiraki Y, Okamoto D, Nishie A, Asayama Y, Ishigami K, Ushijima Y, et al. (August 2019). "Papillary renal cell carcinoma with massive hematoma mimicking hemangioma". Radiology Case Reports. 14 (8): 1003–1006. doi:10.1016/j.radcr.2019.05.025. PMC   6556879 . PMID   31198484.
  34. 1 2 Moch H (July 2016). "[The WHO/ISUP grading system for renal carcinoma]". Der Pathologe. 37 (4): 355–60. doi:10.1007/s00292-016-0171-y. PMID   27271258. S2CID   8644427.
  35. ↑ Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM (July 2016). "The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours". European Urology. 70 (1): 93–105. doi:10.1016/j.eururo.2016.02.029. PMID   26935559.
  36. ↑ Table 3 from: Weiss, Lawrence M.; Gelb, Arnold B.; Jeffrey Medeiros, L. (1995). "Adult Renal Epithelial Neoplasms". American Journal of Clinical Pathology. 103 (5): 624–635. doi:10.1093/ajcp/103.5.624. ISSN   0002-9173. PMID   7741111.
  37. ↑ Liu K, Ren Y, Pang L, Qi Y, Jia W, Tao L, et al. (2015-07-01). "Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study". International Journal of Clinical and Experimental Pathology. 8 (7): 8311–35. PMC   4555730 . PMID   26339402.
  38. 1 2 3 Zarrabi K, Fang C, Wu S (February 2017). "New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy". Journal of Hematology & Oncology. 10 (1): 38. doi: 10.1186/s13045-016-0374-y . PMC   5288948 . PMID   28153029.
  39. ↑ Ravaud, A.; Oudard, S.; De Fromont, M.; Chevreau, C.; Gravis, G.; Zanetta, S.; Theodore, C.; Jimenez, M.; Sevin, E.; Laguerre, B.; Rolland, F.; Ouali, M.; Culine, S.; Escudier, B. (2015-06-01). "First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†". Annals of Oncology. 26 (6): 1123–1128. doi: 10.1093/annonc/mdv149 . PMID   32018840.
  40. ↑ Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH, et al. (March 2010). "Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America". Cancer. 116 (5): 1272–80. doi: 10.1002/cncr.24864 . PMID   20082451. S2CID   205659715.
  41. ↑ Kamai T, Abe H, Arai K, Murakami S, Sakamoto S, Kaji Y, Yoshida KI (March 2016). "Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report". BMC Cancer. 16: 232. doi: 10.1186/s12885-016-2272-7 . PMC   4794818 . PMID   26983443.
  42. ↑ Zanardi E, Verzoni E, Grassi P, Necchi A, Giannatempo P, Raggi D, et al. (June 2015). "Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma". Therapeutic Advances in Urology. 7 (3): 152–61. doi:10.1177/1756287215574457. PMC   4485412 . PMID   26161146.
  43. ↑ Coppin C (May 2010). "Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib". Biologics: Targets and Therapy. 4: 91–101. doi: 10.2147/btt.s6748 . PMC   2880340 . PMID   20531964.
  44. 1 2 Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, et al. (January 2013). "Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma". Journal of Clinical Oncology. 31 (2): 181–6. doi:10.1200/JCO.2012.43.3383. PMC   3532390 . PMID   23213094.
  45. ↑ Nosé V (2020-02-14). Diagnostic Pathology: Familial Cancer Syndromes E-Book. Elsevier Health Sciences. ISBN   978-0-323-71205-7.
  46. 1 2 Bostwick DG, Cheng L (2008-01-01). Urologic Surgical Pathology. Elsevier Health Sciences. ISBN   978-0-323-01970-5.
  47. ↑ "MDEdge Oauth". profreg.medscape.com. Retrieved 2020-04-08.
  48. ↑ Zucchi A, Novara G, Costantini E, Antonelli A, Carini M, Carmignani G, et al. (April 2012). "Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma". BJU International. 109 (8): 1140–6. doi: 10.1111/j.1464-410X.2011.10517.x . PMID   21871053. S2CID   205545457.
  49. ↑ Singh SR, Rameshwar P (2014-04-21). MicroRNA in Development and in the Progression of Cancer. Springer Science & Business. ISBN   978-1-4899-8065-6.
  50. ↑ Fernandes DS, Lopes JM (2015-01-01). "Pathology, therapy and prognosis of papillary renal carcinoma". Future Oncology. 11 (1): 121–32. doi:10.2217/fon.14.133. hdl: 10216/72945 . PMID   25572787.
  51. ↑ Suh JH, Oak T, Ro JY, Truong LD, Ayala AG, Shen SS (2009-01-30). "Clinicopathologic features of renal cell carcinoma in young adults: a comparison study with renal cell carcinoma in older patients". International Journal of Clinical and Experimental Pathology. 2 (5): 489–93. PMC   2655150 . PMID   19294008.
  52. ↑ Batai K, Harb-De la Rosa A, Zeng J, Chipollini JJ, Gachupin FC, Lee BR (November 2019). "Racial/ethnic disparities in renal cell carcinoma: Increased risk of early-onset and variation in histologic subtypes". Cancer Medicine. 8 (15): 6780–6788. doi:10.1002/cam4.2552. PMC   6826053 . PMID   31509346.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.